-

07:04:57 PM

AVIR Stock News

AVIR - Atea Pharmaceuticals Inc

03/14/23 7:00 AM

Nasdaq : AVIR

covid-19

New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C Presented at 2023 International Conference on Antiviral Research

Low risk for drug-drug interactions with bemnifosbuvir based upon results from in vitro metabolism and transporter studies Bemnifosbuvir retains activity against all SARS -CoV-2 variants of concern evaluated as well as other human coronaviruses such as HCoV-229E, HCoV-OC43, and SARS-CoV-1 Favorable

RHEA-AI

neutral

03/08/23 7:00 AM

Nasdaq : AVIR

covid-19

New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C to be Presented at 2023 International Conference on Antiviral Research

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct acting therapeutics for several viral diseases, today announced six upcoming presentations at the 36 th

RHEA-AI

neutral

02/28/23 4:05 PM

Nasdaq : AVIR

earnings

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for treatment of COVID-19 in high-risk patients continues enrollment; interim analysis expected in 2H23 Phase 2 trial evaluating combination of bemnifosbuvir and ruzasvir for treatment of HCV to start enrollment in 2Q23; initial results expected by

RHEA-AI

neutral

02/23/23 7:00 AM

Nasdaq : AVIR

clinical trial

Atea Pharmaceuticals Presents Favorable Drug Interaction Profile of Bemnifosbuvir in Phase 1 Studies at CROI 2023

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that data from three Phase 1 studies

RHEA-AI

neutral

02/21/23 7:00 AM

Nasdaq : AVIR

conferencesearnings

Atea Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Tuesday, February 28, 2023, at 4:30 p.m. ET to report financial results for the

RHEA-AI

neutral

02/15/23 4:05 PM

Nasdaq : AVIR

conferences

Atea Pharmaceuticals to Present Data on Bemnifosbuvir Drug Interaction Profile at Conference on Retroviruses and Opportunistic Infections

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced two upcoming poster presentations at the Conference on Retroviruses and Opportunistic Infections (CROI), which will take place February 19-22,

RHEA-AI

neutral

02/07/23 7:00 AM

Nasdaq : AVIR

conferences

Atea Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, together with other members of the Atea management team, will

RHEA-AI

neutral

01/09/23 7:00 AM

Nasdaq : AVIR

Atea Pharmaceuticals Highlights Strategic Priorities for 2023

Enrollment Progresses in SUNRISE-3 Global Phase 3 Registrational Trial of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19 with Interim Analysis Expected 2H23 Proof-of-Concept Results for AT-752 for Dengue Expected 1Q23 Enrollment Expected to Initiate 2Q23 for Phase 2 Combination

RHEA-AI

neutral

01/04/23 7:00 AM

Nasdaq : AVIR

conferences

Atea Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals, will present a business update at the 41 st

RHEA-AI

neutral

11/29/22 7:00 AM

Nasdaq : AVIR

clinical trialcovid-19

Atea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19

Global Study to Evaluate Bemnifosbuvir as Monotherapy and in Combination in Non-Hospitalized Patients at High Risk of Disease Progression, Regardless of Vaccination Status Phase 3 Evaluation of Bemnifosbuvir Supported by Clinical Data from Late-Stage MORNINGSKY Trial and Prior Studies

RHEA-AI

neutral

1 2 3 4 5 6 7 Next

AVIR Data

IndustryPharmaceutical Preparation Manufacturing
Websiteateapharma.com
Security nameAtea Pharmaceuticals Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees59
Tags
- Health Technology
- Pharmaceuticals: Major

About Atea Pharmaceuticals Inc

Atea is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging its deep understanding of antiviral drug development, nucleoside biology, and medicinal chemistry, the Company has built a proprietary purine nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, the Company is focused on the development of orally available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) infection, and respiratory syncytial virus (RSV).